-

Flatiron Health Names New Chief Business, Technology, and Product Leaders

Michael Bierl, Allison Candido, and Kate Estep assume expanded roles to drive innovation and scale.

NEW YORK--(BUSINESS WIRE)--Flatiron Health is pleased to announce three significant appointments to its Executive Team, reflecting the critical, enterprise-level responsibilities these leaders have assumed and the company’s evolving direction. Michael Bierl will serve as Chief Business Officer, Allison Candido will serve as Chief Technology Officer, and Kate Estep will serve as Chief Product Officer. With decades of combined experience, Bierl, Candido, and Estep bring the leadership and expertise needed to accelerate Flatiron’s strategy and deliver integrated data, intelligence, and point-of-care solutions that can transform cancer care globally.

Michael, Allie, and Kate’s expanded roles enable us to operate with greater clarity, coordination, and focus as we fundamentally transform how we deliver on our mission to improve and extend lives for every person with cancer.

Share

“These appointments reflect where Flatiron is headed as we build an integrated global platform that defines the future of oncology,” said Nathan Hubbard, Chief Executive Officer at Flatiron Health. “Michael, Allie, and Kate’s expanded roles enable us to operate with greater clarity, coordination, and focus as we fundamentally transform how we deliver on our mission to improve and extend lives for every person with cancer."

Michael Bierl, Chief Business Officer
Bierl joined Flatiron in 2019 and has been instrumental in shaping and scaling the company's Global Evidence business and expanding Flatiron's impact, including building and leading the company's European presence. In his role as Chief Business Officer, Bierl leads Flatiron's global commercial, scientific, clinical, operational, and customer-facing teams—reflecting how Flatiron increasingly serves customers and partners through integrated evidence solutions.

Allison Candido, Chief Technology Officer
Candido has been a foundational leader at Flatiron since 2014, bringing deep technical vision and operational excellence to all of her contributions. As Chief Technology Officer, she will continue to lead Flatiron's Engineering organization as the technology evolves its use of AI to unlock data at unprecedented scale and meet the most complex needs of customers in the oncology ecosystem.

Kate Estep, Chief Product Officer
Since joining Flatiron in 2018, Estep has earned a reputation as a deeply trusted leader, known for connecting strategy, product thinking, and customer needs across Flatiron's Point of Care and Global Evidence businesses. As Chief Product Officer, Estep will drive the evolution of Flatiron's Point of Care and Global Evidence product suites, unifying how customers across oncology providers and life sciences leverage data and AI solutions to generate intelligence that enables better decisions for life sciences partners and clinicians, accelerating progress in cancer care.

Bierl, Candido, and Estep join Cal Brouilette, Chief Financial Officer, and Julia Morton, Chief Operating Officer, on Flatiron's Executive Team, all reporting to the CEO Nathan Hubbard.

About Flatiron
Flatiron Health is a healthtech company expanding the possibilities for point of care solutions in oncology and using data for good to power smarter care for every person with cancer. Through machine learning and AI, real-world evidence, and breakthroughs in clinical trials, we continue to transform patients’ real-life experiences into knowledge and create a more modern, connected oncology ecosystem. Flatiron Health is an independent affiliate of the Roche Group.

Contacts

Media Contact
Nina Toor
press@flatiron.com

Flatiron Health

Details
Headquarters: New York, NY
CEO: Carolyn Starrett
Employees: 2,500
Organization: PRI

Release Versions

Contacts

Media Contact
Nina Toor
press@flatiron.com

Social Media Profiles
More News From Flatiron Health

Flatiron Health Attends the 2026 American Society of Genitourinary Cancers Symposium to Answer Oncology's Most Critical Questions

NEW YORK--(BUSINESS WIRE)--Flatiron Health today announced its presence at the American Society of Genitourinary Cancers Symposium happening from February 26-28, 2026, in San Francisco, California. Flatiron's real-world data and research capabilities are featured across multiple presentations, including 6 research acceptances spanning genitourinary cancers. A cornerstone of Flatiron’s presence at ASCO GU 2026 is the global prostate cancer and bladder cancer Panoramic datasets, which draw from o...

Flatiron Launches First-of-Its-Kind AI-Powered Global Prostate Cancer Datasets

NEW YORK--(BUSINESS WIRE)--Flatiron Health, a leading healthtech company dedicated to improving cancer care and advancing research using real-world data, today announced their first Panoramic datasets in the UK and Germany for patients with prostate cancer. Globally, prostate cancer affects nearly 1.5 million patients annually and has a rapidly evolving treatment landscape, yet real-world evidence remains limited and infeasible to study across international borders. Flatiron is the first and on...

Flatiron Health announces research to be presented at the 2025 San Antonio Breast Cancer Symposium

NEW YORK--(BUSINESS WIRE)--Flatiron Health today announced its presence at the San Antonio Breast Cancer Symposium (SABCS) happening from December 9-12, 2025, in San Antonio, Texas. Flatiron's real-world data and research capabilities are featured across multiple acceptances, including three spotlight presentations and four poster presentations that leverage the breadth of Flatiron’s breast cancer solutions. "Breast cancer is the most common cancer in women worldwide, and every patient's journe...
Back to Newsroom